Restoring glutathione as a therapeutic strategy in chronic kidney disease

Elevation of glutathione as a therapeutic strategy in Alzheimer disease.

Oxidative stress has been associated with the onset and progression of mild cognitive impairment (MCI) and Alzheimer disease (AD). AD and MCI brain and plasma display extensive oxidative stress as indexed by protein oxidation, lipid peroxidation, free radical formation, DNA oxidation, and decreased antioxidants. The most abundant endogenous antioxidant, glutathione, plays a significant role in ...

Elevated Glutathione as a Therapeutic Strategy in Alzheimer’s Disease

Alzheimer’s disease (AD) is characterized by progressive loss of memory and cognition. Our laboratory and many others have shown that the AD brain is under extensive oxidative stress. Numerous therapeutic approaches to AD therapy have been hypothesized. Among these are exogenous antioxidants. We suggest that the body’s own endogenous antioxidant systems should be mobilized against the oxidative...

Vitamin deficiencies in chronic kidney disease

Endocrine disorders in chronic kidney disease

Background and Objective: Endocrine disorders are common in patients with chronic kidney disease (CKD). The aim of the present study is reviewing available literature to give a deep understanding of complexities of endocrine disorders in chronic kidney disease. Methods: A narrative reviewing method based on the available literature was approached. Findings: Generally, when renal function de...

Smads as therapeutic targets for chronic kidney disease

Renal fibrosis is a hallmark of chronic kidney disease (CKD). It is generally thought that transforming growth factor-β1 (TGF-β1) is a key mediator of fibrosis and mediates renal scarring positively by Smad2 and Smad3, but negatively by Smad7. Our recent studies found that in CKD, TGF-β1 is not a sole molecule to activate Smads. Many mediators such as angiotensin II and advanced glycation end p...